SAB Biotherapeutics Inc. [NASDAQ: SABS] traded at a high on 04/13/23, posting a 99.71 gain after which it closed the day’ session at $0.76. The company report on April 13, 2023 that SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza.
FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection in patients at high risk for severe complications, including in patients who are immunocompromised.
The results of the trading session contributed to over 26075235 shares changing hands. Over the past one week, the price volatility of SAB Biotherapeutics Inc. stands at 13.95% while the volatility over the past one month is 12.73%.
The market cap for SABS stock reached $40.99 million, with 43.03 million shares outstanding and 36.01 million shares in the current float. Compared to the average trading volume of 38.16K shares, SABS reached a trading volume of 26075235 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about SAB Biotherapeutics Inc. [SABS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SABS shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SABS stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for SAB Biotherapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 05, 2021.
The Average True Range (ATR) for SAB Biotherapeutics Inc. is set at 0.08, with the Price to Sales ratio for SABS stock in the period of the last 12 months amounting to 0.50. The Price to Book ratio for the last quarter was 1.07, with the Price to Cash per share for the same quarter was set at 0.15.
How has SABS stock performed recently?
SAB Biotherapeutics Inc. [SABS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 72.48. With this latest performance, SABS shares gained by 41.85% in over the last four-week period, additionally sinking by -8.58% over the last 6 months – not to mention a drop of -71.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SABS stock in for the last two-week period is set at 71.33, with the RSI for the last a single of trading hit 78.77, and the three-weeks RSI is set at 65.10 for SAB Biotherapeutics Inc. [SABS]. The present Moving Average for the last 50 days of trading for this stock 0.5845, while it was recorded at 0.4745 for the last single week of trading, and 0.8416 for the last 200 days.
SAB Biotherapeutics Inc. [SABS]: Deeper insight into the fundamentals
Return on Total Capital for SABS is now -326.75, given the latest momentum, and Return on Invested Capital for the company is -77.96. Return on Equity for this stock declined to -88.91, with Return on Assets sitting at -43.03. When it comes to the capital structure of this company, SAB Biotherapeutics Inc. [SABS] has a Total Debt to Total Equity ratio set at 17.49. Additionally, SABS Total Debt to Total Capital is recorded at 14.89, with Total Debt to Total Assets ending up at 8.50. Long-Term Debt to Equity for the company is recorded at 14.05, with the Long-Term Debt to Total Capital now at 11.96.
Reflecting on the efficiency of the workforce at the company, SAB Biotherapeutics Inc. [SABS] managed to generate an average of -$123,342 per employee.SAB Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
Insider trade positions for SAB Biotherapeutics Inc. [SABS]
There are presently around $2 million, or 7.80% of SABS stock, in the hands of institutional investors. The top three institutional holders of SABS stocks are: FIRST PREMIER BANK with ownership of 807,535, which is approximately 0% of the company’s market cap and around 25.00% of the total institutional ownership; VANGUARD GROUP INC, holding 701,584 shares of the stock with an approximate value of $0.27 million in SABS stocks shares; and LMR PARTNERS LLP, currently with $0.2 million in SABS stock with ownership of nearly New of the company’s market capitalization.
19 institutional holders increased their position in SAB Biotherapeutics Inc. [NASDAQ:SABS] by around 1,653,618 shares. Additionally, 17 investors decreased positions by around 288,722 shares, while 13 investors held positions by with 2,712,848 shares. The mentioned changes placed institutional holdings at 4,655,188 shares, according to the latest SEC report filing. SABS stock had 10 new institutional investments in for a total of 1,090,921 shares, while 8 institutional investors sold positions of 89,069 shares during the same period.